The Boom Enters New Phase
The artificial intelligence boom is entering a new phase, one defined less by infrastructure and more by real-world application. Nowhere is that shift more visible than in biotech, where data, diagnostics, and drug discovery are converging into a high-stakes innovation race. Recent developments across public markets show both the promise and the volatility of this transition, as capital flows toward platforms capable of turning complex biological data into actionable outcomes. $KBLB, $BFRG, $RZLV, $ELAB, $EEIQ, $ITRM